期刊
HEALTHCARE
卷 10, 期 8, 页码 -出版社
MDPI
DOI: 10.3390/healthcare10081392
关键词
generics; bioequivalence; substitution; biocreep; narrow therapeutic index drugs
The prescription of generic drugs is an important cost-containment strategy in health systems. Regulatory authorities encourage or require the use of generic drugs due to their lower price compared to brand-name alternatives. However, drug substitution can be critical, especially for drugs with a narrow therapeutic index. Additionally, generics cannot be automatically considered bioequivalent due to the biocreep phenomenon.
The prescription of generic drugs represents one of the main cost-containment strategies of health systems, aimed at reducing pharmaceutical expenditure. In this context, most regulatory authorities encourage or obligate dispensing generic drugs because they are far less expensive than their brand-name alternatives. However, drug substitution can be critical in particular situations, such as the use of drugs with a narrow therapeutic index (NTI). Moreover, generics cannot automatically be considered bioequivalent with each other due to the biocreep phenomenon. In Italy, the regulatory authority has established the Transparency Lists which include the medications that will be automatically substituted for brand-name drugs, except in exceptional cases. This is a useful tool to guide prescribers and guarantee pharmaceutical sustainability, but it does not consider the biocreep phenomenon.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据